Hinge Health price target raised to $79 from $63 at Truist

Truist analyst Jailendra Singh raised the firm’s price target on Hinge Health (HNGE) to $79 from $63 and keeps a Buy rating on the shares. The firm cites the company’s Q1 earnings beat, also stating that while traditional channels – email, postcards – still account for a majority of sign-ups, the management expects HingeConnect-driven enrollment to become a dominant growth lever over time, supporting both higher yield and better retention, the analyst tells investors in a research note.